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Original Article
The association of the eﬀect of lithium in the
maintenance treatment of bipolar disorder
with lithium plasma levels: a post hoc analysis
of a double-blind study comparing switching
to lithium or placebo in patients who
responded to quetiapine (Trial 144)
Nolen WA, Weisler RH. The association of the eﬀect of lithium in the
maintenance treatment of bipolar disorder with lithium plasma levels: a
post hoc analysis of a double-blind study comparing switching to
lithium or placebo in patients who responded to quetiapine (Trial 144).
Bipolar Disord 2013: 15: 100–109.  2012 John Wiley & Sons A ⁄S.
Published by Blackwell Publishing Ltd.
Objectives: There is no robust proof that the eﬃcacy of lithium in the
prevention of manic and depressive episodes in bipolar disorder depends
on its plasma level. This analysis aimed to compare the eﬀect of lithium
within the presumed therapeutic range of 0.6–1.2 mEq ⁄L and below
0.6 mEq ⁄L with that of placebo.
Methods: We carried out a post hoc analysis of a double-blind trial in
which patients aged ‡18 years with bipolar I disorder (DSM-IV) who
had achieved stabilization from a manic, depressive, or mixed episode
during open-label treatment with quetiapine were randomized to
continue quetiapine or to switch to lithium or placebo for up to
104 weeks. Of patients randomized to lithium, 201 obtained median
lithium levels between 0.6 and 1.2 mEq ⁄L, and 137 obtained median
lithium levels <0.6 mEq ⁄L. Their outcomes were compared with those
of patients receiving placebo (n = 404). The primary outcome was time
to recurrence of any mood event; additional outcomes included time to
recurrence of a manic or depressive event.
Results: Times to recurrence of any mood event as well as a manic or
depressive event were signiﬁcantly longer for the lithium 0.6–1.2 mEq ⁄L
group versus placebo and versus lithium <0.6 mEq ⁄L, with no
diﬀerences between lithium <0.6 mEq ⁄L and placebo.
Conclusions: The results support and expand previous ﬁndings that
lithium should be dosed high enough to achieve plasma levels
‡0.6 mEq ⁄L in order to achieve an eﬀect in the prevention of both manic
and depressive recurrences of bipolar I disorder. A major limitation is
that the composition of the two lithium groups was not based on
randomization.
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Bipolar I disorder is characterized by recurrent
manic and depressive episodes. Therefore, treat-
ment should be aimed not only at reducing the
symptoms of acute manic and depressive episodes,
but also at preventing further recurrences (mainte-
nance treatment). In the 1970s, lithium was the ﬁrst
drug approved in the USA as well as many other
countries for the maintenance treatment of bipolar
disorder. Although, since then, several other drugs
have become available for the maintenance treat-
ment of bipolar disorder (such as valproate,
olanzapine, quetiapine, aripiprazole, and lamotri-
gine) (1–11), lithium has remained a ﬁrst-line
option (12–14). This position was supported by a
systematic review and meta-analysis of ﬁve ran-
domized controlled trials (n = 770) that compared
lithium with placebo in the maintenance treatment
of bipolar disorder, excluding trials that randomly
assigned patients who had been stable on long-
term lithium to continue or discontinue lithium.
The review found eﬃcacy for lithium in the
prevention of any mood episode and manic
episodes, but less unequivocal results regarding
the prevention of depressive episodes (15).
A disadvantage of lithium is its small therapeutic
window. At higher dosages leading to lithium
plasma levels above 1.2 mEq ⁄L, there is an
increased risk of adverse eﬀects and even toxicity.
On the other hand, too-low dosages and corre-
sponding too-low lithium levels are associated with
insuﬃcient eﬀect. Therefore, guidelines recommend
monitoring lithium levels in patients for an optimal
eﬀect and tolerance (12, 13). It is still unclear,
however, what the most eﬃcacious and, especially,
what the minimum lithium level should be.
While Schou and Baastrup (16), who developed
the use of lithium in the maintenance treatment of
bipolar disorder, recommended treating patients
with lithium levels of at least 0.6 mEq ⁄L, they
never evaluated the optimum lithium level in a
controlled study. A recent review (17) identiﬁed
ﬁve randomized, controlled studies (N = 266) that
addressed this question, although with diﬀerent
methodologies. In four studies, patients (n = 197)
were randomized to low or high lithium levels after
having received open treatment with lithium; in the
ﬁfth study, patients (n = 69) were directly ran-
domized in four groups. The results suggest that
lithium levels <0.4 mEq ⁄L are ineﬀective, while
lithium levels >0.75 mEq ⁄L may not confer addi-
tional advantage. The conclusions of the review are
hampered by various methodological limitations:
(i) diﬀerences in whether patients had already
received lithium prior to randomization; (ii) diﬀer-
ent lithium levels being compared; (iii) diﬀerent
outcome parameters; (iv) not all studies used
intent-to-treat (ITT) analysis; and (v) none of the
studies had a placebo arm. Furthermore, the
poorer outcome of lower lithium levels in some
patients may have resulted from acute reduction of
lithium level in patients who were randomized to
low lithium levels after receiving lithium at higher
levels prior to randomization (18).
In another attempt to investigate whether the
eﬀect of lithium depends on its level, Severus et al.
(19) performed a post hoc analysis of a study in
which patients who had remitted from a manic
episode during treatment with the combination of
olanzapine and lithium were subsequently rando-
mized to continue double-blind treatment with
either olanzapine (n = 217) or lithium alone
(n = 214) (20). Lithium levels were aimed to be
between 0.6 and 1.2 mEq ⁄L, but actual lithium
levels at randomization were <0.6 mEq ⁄L (n =
14), 0.6–0.8 mEq ⁄L (n = 70), and >0.8 mEq ⁄L
(n = 128). The lithium <0.6 mEq ⁄L group had
a signiﬁcantly increased risk for manic ⁄mixed,
but not depressive, episodes compared with the
combined lithium 0.6–1.2 mEq ⁄L group, sug-
gesting that lithium levels should be above
0.6 mEq ⁄L to be eﬃcacious, at least against mania.
A major limitation of this study is that it had no
placebo arm.
The objective of the current paper is to describe
the results of a post hoc analysis of a randomized,
controlled, double-blind trial in which bipolar I
disorder patients who achieved stabilization on
open-label quetiapine (300–800 mg ⁄day) over
4–24 weeks were randomized to continue quetia-
pine or to switch to lithium (0.6–1.2 mEq ⁄L) or
placebo for up to 104 weeks (21). Both continua-
tion of quetiapine and switching to lithium signiﬁ-
cantly increased time to recurrence of any mood
episode (the primary outcome criterion) as well as
time to manic or depressive episodes when com-
pared with switching to placebo. Of the 418
patients randomized to lithium in this trial, 54
were excluded from the ITT population due to
inadequate monitoring of their lithium level. Of the
remaining 364 patients, 163 patients did not have a
median lithium level within the predeﬁned range of
0.6–1.2 mEq ⁄L; in most of these cases lithium
levels were <0.6 mEq ⁄L. This created the oppor-
tunity to compare two groups of patients receiving
lithium (with lithium levels <0.6 mEq ⁄L and 0.6–
1.2 mEq ⁄L) against those receiving placebo.
Methods
In this paper, we describe only a part of Trial 144:
the outcome of patients who were randomized to
switch to lithium or placebo. The study design,
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including key inclusion and exclusion criteria and
the per-protocol amendment that led to prema-
ture discontinuation of the study after interim
analysis showed a positive outcome for quetiapine
versus placebo, is described in detail elsewhere
(21).
The study was conducted in 15 countries in Asia,
Europe, Central and South America, and the USA;
adhered to the current amendment of the Decla-
ration of Helsinki and International Conference on
Harmonisation ⁄Good Clinical Practice guidelines;
and was approved by the ethical review boards of
participating centers. Written informed consent
was obtained from all patients after complete
description of the study.
Patients
In short, 2438 patients aged ‡18 years with bipolar
I disorder (DSM-IV) with ‡ one previous episode
in the last two years and a current (or documented
recent) manic, depressive, or mixed episode started
open-label treatment with quetiapine (300–800
mg ⁄day, depending on eﬃcacy and tolerance)
for up to 24 weeks. Exclusion criteria included
intolerance or lack of response to quetiapine or
lithium and regular contraindications to lithium.
Patients who achieved stabilization by at least
week 20 and who maintained stability for at least
four subsequent weeks [deﬁned by a Young Mania
Rating Scale (YMRS) total score £12 (22) and a
Montgomery-A˚sberg Depression Rating Scale
(MADRS) total score £12 (23)] subsequently
entered the double-blind, randomized phase, which
was planned for up to 104 weeks. During this
phase, patients either continued quetiapine or were
gradually switched to placebo or lithium.
Study medication
Study medications (quetiapine, lithium, or placebo)
were administered twice daily using a double-
dummy design. The quetiapine tablets used during
the prerandomization phase were systematically
replaced with placebo tablets during the ﬁrst two
weeks following randomization. Lithium was
started at 600 mg ⁄day and increased to 900 mg ⁄day
at day 4. Blood samples were taken for determina-
tion of trough serum lithium levels after two weeks
and subsequently at every visit, and lithium doses
were adjusted to obtain lithium levels between 0.6
and 1.2 mEq ⁄L. To ensure blinding of lithium
treatment, a programmed automatic system sent a
reply for each blood sample and suggested a change
in medication dosage for lithium or dummy recom-
mendations for placebo.
Patients were allowed to continue medications
for non-psychiatric illnesses unless these medi-
cations were associated with known signiﬁcant
interactions with study medications. Low doses
of zolpidem tartrate (maximum 10 mg ⁄day),
zaleplon (maximum 20 mg ⁄day), zopiclone (maxi-
mum 7.5 mg ⁄day), and chloral hydrate (maximum
1 g ⁄day) for insomnia; lorazepam (maximum
2 mg ⁄day) for anxiety; and anticholinergic medi-
cations for extrapyramidal symptoms were permit-
ted throughout the study. No other psychoactive
medications were allowed in the four weeks prior
to randomization or during the randomized phase.
Outcome measures
The primary outcome measure was the time to
recurrence of any mood event (manic, depressive,
or mixed). Recurrence was deﬁned as at least one of
the following: initiation of an antipsychotic, anti-
depressant, anxiolytic (other than lorazepam), or
other medication to treat a mood event; hospital-
ization for a mood event; YMRS score ‡20 (mania)
or MADRS score ‡20 (depression) at two consec-
utive assessments or ﬁnal assessment if the patient
discontinued; or discontinuation from the study
if this, according to the investigator, was due to a
mood event.
Secondary outcome measures included time to
recurrence of a manic or depressive event, time to
all-cause discontinuation (deﬁned as premature
discontinuation due to a mood event or any other
reason), and interepisodic mood symptoms [via
assessment of severity of manic and depressive
symptoms using YMRS, MADRS, and Clinical
Global Impression-Bipolar (CGI-BP) Severity of
Illness and Global Improvement rating scales (24)].
Assessments during the randomized phase were
performed at weeks 0, 1, 2, 4, 6, and 8, and
thereafter every four weeks to week 104. For the
complete overview of all secondary outcome mea-
sures, see the primary publication of the study (21).
Adverse events
The incidence and severity of adverse events and
withdrawals due to adverse events were recorded at
each assessment based on the total population that
received medication. Adverse events were reported
using Medical Dictionary for Regulatory Activities
terminology (http://www.meddramsso.com/).
Safety measures (laboratory assessments, vital
signs, weight and body mass index, electrocardio-
gram, movement disorders, and suicidality) are not





Time to recurrence of any mood event, manic
event, or depressive event was analyzed by Cox
proportional hazards modeling, with geographical
region included as covariate (patients with mixed
symptoms were allocated by investigators to
groups according to predominance of manic or
depressive symptoms). Hazard ratios (HRs) for
time to recurrence, with corresponding 95% con-
ﬁdence intervals (CIs), were determined between
treatment arms. The time to event was censored
when a patient completed or discontinued the
study without experiencing a manic or depressive
event. Times to any mood, manic, and depressive
events and time to all-cause discontinuation were
additionally explored by Kaplan–Meier estimates
and curves. Patients not experiencing an event
before the end of the trial (including those who
discontinued after interim analysis) were censored.
YMRS, MADRS, and CGI-BP scores were
analyzed using analysis of covariance. Importantly,
as no patients in the lithium <0.6 mEq ⁄L group
even remained in the study after 44 weeks, a
mixed-model repeated measures analysis, as
described in the primary publication (21), could
not be performed. The mean of all assessments
between randomization and up to, but excluding,
the visit where a mood event was recorded was
analyzed. Treatment and geographic region were
included in the model as ﬁxed eﬀects and score at
randomization as covariate. The ITT population
was used for all eﬃcacy analyses.
Descriptive statistics were used to report adverse
events and included all patients who received
treatment during the randomized phase.
All statistical tests are two-tailed and a p-value
<0.05 is considered statistically signiﬁcant. No
adjustment for multiplicity was carried out and all
p-values are nominal; thus, caution should be
exercised when analyzing the results.
Results
In total, 2438 patients were enrolled in the pre-
randomization phase (n = 1174 manic; n = 710
depressive; n = 554mixed-index episode), of whom
1226 (50.3%) were randomized and 1172 (95.6%)
were included in the total ITT population (n = 404
quetiapine; n = 364 lithium; n = 404 placebo)
(Fig. 1). In this paper, we focus on the results in the
patients who were switched to lithium and who
obtained a median lithium level <0.6 mEq ⁄L
(lithium <0.6 group; n = 137) or between 0.6 and
1.2 mEq ⁄L (lithium 0.6–1.2 group; n = 201) versus
those in patients who were switched to placebo
(n = 404).Eightpatientswithamedian lithiumlevel
>1.2 mEq ⁄L were not included in the analysis, as
well as 18 patients who did not have any lithium
assessment.
Demographic baseline disease characteristics did
not diﬀer between patients in the two lithium
groups and the placebo group (Table 1). Use of
lorazepam, sleep medication, and anticholinergic
drugs was similar across treatment groups.
The means of the patients individual median
lithium levels were 0.33 [standard devia-
tion (SD) = 0.15] mEq ⁄L in the lithium <0.6
group (with 56 patients between 0.4 and <0.6
mEq ⁄L, and 81 patients <0.4 mEq ⁄L) and 0.77
(SD = 0.13) mEq ⁄L in the lithium 0.6–1.2 group.
Efficacy measures
The time to recurrence of any mood event (the
primary outcome measure), as well as of a manic or
depressive event, was signiﬁcantly longer in the
lithium 0.6–1.2 group compared with the placebo
group as well as the lithium <0.6 group, while
these measures were not diﬀerent between the
lithium <0.6 group and the placebo group
(Table 2 and Figs. 2–4). The HR for the time to
recurrence of any mood event for lithium 0.6–1.2
versus placebo was 0.32 (95% CI: 0.23–0.44;
p < 0.0001), corresponding to a risk reduction of
68%. There were no signiﬁcant diﬀerences between
lithium <0.6 and placebo on these outcome
measures. On the recommendation of the review-
ers, we also performed a multivariate Cox regres-
sion analysis with inclusion of potential
confounders (gender, type of index episode, rapid
cycling, and YMRS and MADRS score at ran-
domization) that were not distributed equally over
the three groups. This analysis yielded essentially
the same results (Table 2).
When data were stratiﬁed by index episode
(manic, depressive, or mixed), lithium 0.6–1.2
mEq ⁄L was signiﬁcantly more eﬀective than pla-
cebo in six of the nine outcome measures and was
more eﬀective than lithium <0.6 mEq ⁄L in three
of the nine outcome measures, while lithium <0.6
mEq ⁄L was not diﬀerent from placebo (see Sup-
plementary Table 1).
Lithium 0.6–1.2 mEq ⁄L was also associated
with signiﬁcant improvements, compared with
placebo, in interepisode scores on the YMRS,
MADRS, CGI-BP Severity of Illness, and CGI-BP
Global Improvement scales and, compared with
lithium <0.6 mEq ⁄L, on the CGI-BP Severity of
Illness scale (see Supplementary Table 2). Again,
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lithium <0.6 mEq ⁄L was not diﬀerent from
placebo.
Time to all-cause discontinuation showed a
diﬀerent pattern: it was longest in the lithium
0.6–1.2 group (median 169 days), shortest in the
lithium <0.6 group (median 57 days), and inter-
mediate for the placebo group (median 76 days)
(Fig. 5).
In addition to the cutoﬀ of 0.6 mEq ⁄L, our data
also allow comparisons of patients using other
cutoﬀs, for example, patients with a median
lithium level <0.4 (n = 81, 22.3%), between 0.4
and <0.6 (n = 56, 15.4%), between 0.6 and <0.8
(n = 118, 32.4%), between 0.8 and <1.0 (n = 68,
18.7%), and between 1.0 and 1.2 mEq ⁄L (n = 15,
4.1%). On the primary outcome measure
(recurrence of any mood event), the HRs versus
placebo were 0.66 (95% CI: 0.42–1.03; p = 0.065)
for lithium <0.4 mEq ⁄L; 1.05 (95% CI: 0.67–1.63;
p = 0.85) for lithium 0.4 to <0.6 mEq ⁄L; 0.35
(95% CI: 0.23–0.52; p < 0.0001) for lithium 0.6 to
<0.8 mEq ⁄L; 0.24 (95% CI: 0.14–0.42; p <
0.0001) for lithium 0.8 to <1.0 mEq ⁄L; and 0.50
(95% CI: 0.21–1.22; p = 0.13) for lithium 1.0–1.2
mEq ⁄L.
Safety and tolerability measures
During the randomized phase, 111 (62.0%) patients
in the lithium<0.6 group and 126 (59.2%) patients
in the lithium 0.6–1.2 group reported an adverse
event, versus 228 (56.4%) patients receiving
placebo. These events were considered drug-related
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Fig. 1. Flowchart of the study. ITT = intent-to-treat.
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patients, and led to discontinuation in seven
(3.9%), eight (3.8%), and 12 (3.0%) patients,
respectively. Serious adverse events were reported
by ﬁve (2.8%) patients in the lithium <0.6 group,
two (0.9%) in the lithium 0.6–1.2 group, and 11
(2.7%) in the placebo group. Detailed information
on adverse events occurring in ‡5% of any group is
presented in Supplementary Table 3, together with
Table 1. Demographic and current illness characteristics of all patients at enrollment and of patients in the two lithium groups (<0.6 mEq ⁄ L and 0.6–
1.2 mEq ⁄ L) and the placebo group at randomization
Prerandomization phase
(open-label quetiapine) Randomized phase
Patients enrolled
(N = 2438)
Lithium <0.6 mEq ⁄ L
(n = 137)
Lithium 0.6–1.2




Male 1131 (46.4) 48 (35.0) 99 (49.3) 210 (52.0)
Female 1307 (53.6) 89 (65.0) 102 (50.7) 194 (48.0)
Age, years, mean (SD) 38.4 (12.3) 36.9 (11.7) 39.3 (12.8) 40.0 (12.9)
Most recent episode, n (%)
Mania 1174 (48.2) 56 (40.9) 122 (60.7) 223 (55.2)
Depression 710 (29.1) 41 (29.9) 53 (26.4) 115 (28.5)
Mixed 554 (22.7) 40 (29.2) 26 (12.9) 66 (16.3)
With rapid-cycling course, n (%)
Yes 470 (19.3) 25 (18.2) 22 (10.9) 47 (11.6)
Unknown 2 (0.1) 1 (0.7) 0 (0) 0 (0)
YMRS total score at randomization, mean (SD)
Overall 15.8 (10.0) 4.2 (3.5) 3.3 (3.4) 3.7 (3.6)
Index episode
Maniaa 20.9 (8.8) 5.1 (3.8) 3.8 (3.5) 4.2 (3.8)
Depressionb 6.3 (5.7) 3.1 (3.3) 2.0 (2.9) 2.3 (2.7)
Mixedc 17.3 (7.8) 4.0 (2.9) 3.5 (3.4) 4.4 (3.4)
MADRS total score at randomization, mean (SD)
Overall 15.1 (11.1) 4.4 (3. 8) 2.6 (3.1) 3.4 (3.4)
Index episode
Maniaa 6.8 (5.8) 2.8 (3.2) 1.9 (2.6) 2.4 (2.7)
Depressionb 24.4 (8.3) 5.5 (3.8) 3.9 (3.3) 4.8 (3.9)
Mixedc 20.9 (9.6) 5.4 (3.8) 3.4 (3.8) 4.3 (3.6)
MADRS = Montgomery-A˚sberg Depression Rating Scale; SD = standard deviation; YMRS = Young Mania Rating Scale.
aIn the prerandomization phase, n = 1174; in the randomized phase, n = 56 for lithium <0.6 mEq ⁄ L, n = 122 for lithium 0.6–1.2 mEq ⁄ L,
and n = 222 or 223 for placebo.
bIn the prerandomization phase, n = 710; in the randomized phase, n = 41 for lithium <0.6 mEq ⁄ L, n = 53 for lithium 0.6–1.2 mEq ⁄ L,
and n = 115 for placebo.
cIn the prerandomization phase, n = 544; in the randomized phase, n = 40 for lithium <0.6 mEq ⁄ L, n = 26 for lithium 0.6–1.2 mEq ⁄ L,
and n = 66 for placebo.
Table 2. Hazard ratios for time to recurrence of any mood event (primary outcome measure), manic event, or depressive event
Recurrent event
Any mood event Manic event Depressive event
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Lithium <0.6 mEq ⁄ L versus
placebo
0.79 0.57–1.10 0.1674 0.68 0.42–1.11 0.1272 0.91 0.57–1.45 0.6920
Adjusteda 0.78 0.56–1.10 0.1551 0.69 0.42–1.13 0.1370 0.88 0.54–1.41 0.5860
Lithium 0.6–1.2 mEq ⁄ L versus
placebo
0.32 0.23–0.44 <0.0001 0.26 0.17–0.41 <0.0001 0.41 0.25–0.66 0.0003
Adjusteda 0.32 0.23–0.44 <0.0001 0.26 0.17–0.41 <0.0001 0.42 0.26–0.68 0.0005
Lithium < 0.6 mEq ⁄ L versus
lithium 0.6–1.2 mEq ⁄ L
2.23 1.38–3.59 0.0010 2.43 1.22–4.84 0.0117 2.06 1.07–3.99 0.0309
Adjusteda 2.16 1.32–3.53 0.0021 2.23 1.11–4.49 0.0247 1.95 0.98–3.89 0.0563
CI = confidence interval; HR = hazard ratio.
aAdjusted for gender, type of index episode, rapid cycling, and Young Mania Rating Scale and Montgomery-A˚sberg Depression Rating
Scale scores at randomization.
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incidence densities that adjust for diﬀerent dura-
tions of treatment.
Discussion
For the main ﬁndings of the study (both the
continuation of quetiapine and switching to lith-
ium were found to be more eﬀective than placebo
in preventing recurrence of any mood event as well
as preventing manic and depressive events in
patients who had responded to quetiapine for the
treatment of an acute manic, depressed, or mixed
episode), we refer to the primary publication (21).
An interesting aspect (and problem) of the study is
that 137 patients in the lithium group had median
plasma levels below the predeﬁned range of 0.6–
1.2 mEq ⁄L. This created the opportunity to
compare the eﬀect of lithium in two groups of
patients, with mean plasma levels between 0.6 and
1.2 mEq ⁄L and below 0.6 mEq ⁄L. Moreover, we
could, for the ﬁrst time, compare both groups with
a group receiving placebo. The major ﬁnding of
these comparisons is that, compared to placebo,
lithium 0.6–1.2 mEq ⁄L prevented the recurrence of
any mood event and also of a manic and a
depressive event, while this was not the case in
the lithium <0.6 group. Moreover, lithium 0.6–1.2
mEq ⁄L was more eﬀective than lithium <0.6
mEq ⁄L on these outcome measures.
When further divided into smaller subgroups,
both lithium 0.6 to <0.8 mEq ⁄L and lithium 0.8 to
<1.0 mEq ⁄L were more eﬀective than placebo in
preventing any mood episode, while lithium <0.4
mEq ⁄L and lithium 0.4 to <0.6 mEq ⁄L were not,
indicating that the cutoﬀ for an eﬀective plasma
level of lithium is more likely to be around
0.6 mEq ⁄L than around 0.4 mEq ⁄L. This supports
and expands the ﬁndings of meta-analyses of
previous randomized studies which, however, did
not have placebo arms (15, 18).
We consider these ﬁndings especially important
as, for lithium, the study did not have a so-called
enriched design; patients were not selected for prior
response to lithium, but were all responders to
Fig. 2. Time to recurrence of any mood event (primary out-
come measure, Kaplan–Meier curves). PLA = placebo;
Li = lithium.
Fig. 4. Time to recurrence of a depressive event (Kaplan–
Meier curves). PLA = placebo; Li = lithium.
Fig. 5. Time to all-cause discontinuation (Kaplan–Meier
curves). PLA = placebo; Li = lithium.
Fig. 3. Time to recurrence of a manic event (Kaplan–Meier
curves). PLA = placebo; Li = lithium.
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quetiapine. Thus, these results are quite a fair
analysis of lithium eﬃcacy, with no bias at all in
favor of lithium per se. Nevertheless, the results
must also be interpreted with care, as a major
limitation of this study is that patients were not
randomized to either lithium <0.6 mEq ⁄L or
lithium 0.6–1.2 mEq ⁄L; the composition of these
groups was the result of how dosing and adherence
transpired in a study that aimed to obtain lithium
levels between 0.6 and 1.2 mEq ⁄L in all patients
who were switched to lithium. Therefore, the
possibility exists that channeling occurred, i.e.,
there may have been a common underlying
reason(s) why patients who failed to reach prede-
ﬁned levels also had a poorer outcome. However, a
multivariate Cox regression analysis with inclusion
of potential confounders (gender, type of index
episode, rapid cycling, and YMRS and MADRS
scores at randomization) indicates that at least the
unequal distribution of these patient characteristics
over the three groups does not explain the diﬀer-
ences found between the three groups.
It is not completely clear why so many patients
receiving lithium (n = 137; 37.6%) did not reach
predeﬁned lithium levels. With a mean and median
stay in the study of about two months in the
lithium <0.6 group, one would expect that more
patients would have reached predeﬁned levels. In a
normal clinical setting, when the clinician can
decide on dosing based on full information on the
actual lithium level, this is possible within several
weeks. We tend to believe that procedures speciﬁc
to blinded dose adjustments in this study might
have played a role. For instance, achieving prede-
ﬁned levels was possible in another double-blind
study comparing lithium with carbamazepine,
which were both dosed according to predeﬁned
plasma levels (25). In that study, clinicians received
blinded information on plasma levels in x U ⁄L,
corresponding to either 0.x mEq ⁄L for lithium or
x mg ⁄L for carbamazepine, after which the clini-
cian could decide to increase the number of blinded
medications (either lithium or carbamazepine and
dummy placebos). This method resulted in lithium
levels outside the predeﬁned range in six out of 44
patients (13.6%) after 30 days and in only two
patients (4.6%) after 60 days. The advantage of the
latter study is that it was performed in 15 sites from
one small country (The Netherlands), while the
current study involved 128 sites in 15 countries.
Nonadherence to study medication is also
thought to be implicated in the failure to achieve
predeﬁned lithium levels, based on the observation
that the dropout rate (indicated by a shorter mean
time to all-cause discontinuation) was greater in
the lithium <0.6 group than in the lithium 0.6–1.2
group. A related explanation is that adverse events
in the lithium <0.6 group may have prevented
some clinicians from increasing the dose as recom-
mended based on the (blinded) lithium level
assessments. This is, however, not supported by
the occurrence of adverse events that led to early
discontinuation, which was low (below 4%) in all
three groups. Nevertheless, it is possible that some
patients were very sensitive to adverse events, had
their dose reduced, and ultimately were maintained
on lower levels, suggesting that individual patients
might be managed on lower levels.
A remarkable result of the overall analysis of
patients receiving lithium (the ITT group) is that
lithium prevented both manic and depressive
events (21). This contrasts with the results of the
meta-analysis by Geddes et al. (15) of previous
long-term studies with lithium, reporting signiﬁ-
cant eﬃcacy for lithium in the prevention of manic
but not depressive episodes. When this new study
was added to this meta-analysis, the prevention of
depressive episodes also became signiﬁcant (J. R.
Geddes, personal communication).
In conclusion, despite the fact that the current
data are the result of a post hoc analysis and
therefore formally need to be replicated in another
study before deﬁnite conclusions can be drawn, the
results clearly support and expand previous ﬁnd-
ings that lithium should be dosed high enough to
achieve plasma levels of at least 0.6 mEq ⁄L—if
tolerated and not contra-indicated—in order to
achieve a clinically signiﬁcant eﬀect in the preven-
tion of manic as well as depressive episodes of
bipolar I disorder. Patients and their families need
to be educated about this in order for them to
beneﬁt from the preventive eﬀect of lithium, and
advised that failure to achieve and maintain such
levels can result in poorer health outcomes and
higher total medical costs (26).
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